Trial of Lenalidomide in Patients With Lymphoma of the Mucosa Associated Lymphoid Tissue (MALT) Type

Inclusion Criteria: * Patients with histologically confirmed MALT lymphoma with measurable disease (stage I - IV) * With first or greater relapse after HP-eradication, radiation or chemotherapy in case of gastric lymphoma * Age \> 18 years * Must be able to tolerate therapy, and have adequate cardiac, renal, and hepatic function, ECOG status of 0 - 2 * Must be capable of understanding the purpose of the study and have given written informed consent Exclusion Criteria: * Lymphoma histology other than MALT lymphoma or MALT lymphoma with a diffuse large cell lymphoma ("high grade lymphoma") - component * Use of any investigational agent within 28 days prior to initiation of treatment with lenalidomide * History of malignancy other than squamous cell carcinoma, basal cell carcinoma of the skin or carcinoma in situ of the cervix within the last 5 years * Major surgery, other than diagnostic surgery, within the last 4 weeks * Evidence of CNS involvement * A history of uncontrolled seizures, central nervous system disorders or psychiatric disability judged by the investigator to be clinically significant and adversely affecting compliance to study drugs * Severe peripheral polyneuropathy * Clinically significant cardiac disease (e.g., congestive heart failure, symptomatic coronary artery disease and cardiac arrhythmias not well controlled with medication) or myocardial infarction within the last 6 months * Inadequate hematological status at baseline prior to study entry: Dependency on red blood cell and/or platelet transfusions, ANC (absolute neutrophil count (segmented + bands)) \< 1.0 x 109/L * Patients with active opportunistic infections * Pregnancy * Uncontrolled diabetes mellitus * Preexisting thromboembolic events at start of study